Analysts' ratings for Surgery Partners SGRY over the last quarter vary from bullish to bearish, as provided by 7 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 5 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 3 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Surgery Partners, presenting an average target of $38.43, a high estimate of $50.00, and a low estimate of $34.00. Observing a downward trend, the current average is 6.27% lower than the prior average price target of $41.00.
Diving into Analyst Ratings: An In-Depth Exploration
The standing of Surgery Partners among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ben Hendrix | RBC Capital | Lowers | Outperform | $35.00 | $49.00 |
| Tao Qiu | Macquarie | Maintains | Outperform | $34.00 | $34.00 |
| Tao Qiu | Macquarie | Lowers | Outperform | $34.00 | $35.00 |
| Tao Qiu | Macquarie | Maintains | Outperform | $35.00 | $35.00 |
| A.J. Rice | UBS | Announces | Buy | $38.00 | - |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $43.00 | $43.00 |
| Bill Sutherland | Benchmark | Maintains | Buy | $50.00 | $50.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Surgery Partners. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Surgery Partners compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Surgery Partners's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Capture valuable insights into Surgery Partners's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Surgery Partners analyst ratings.
Discovering Surgery Partners: A Closer Look
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It operates in two segments: Surgical Facility Services and Ancillary Services out of which the Surgical Facility Services segment accounts for the majority of revenue.
Breaking Down Surgery Partners's Financial Performance
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Surgery Partners showcased positive performance, achieving a revenue growth rate of 14.29% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Surgery Partners's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -4.11%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Surgery Partners's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.65% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Surgery Partners's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.42%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Surgery Partners's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.86.
How Are Analyst Ratings Determined?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
